Header
An experimental drug achieves the alzhéimer
An experimental drug achieves the alzhéimer
Summary
This news speaks of a new breakthrough in the fight against Alzheimer's carried out by the company Grifols that develops its activity in Spain and the US. The test consists of combining plasma extraction and replacing it with an albumin solution that is a plasma protein. The results of this trial have been very promising, as they have managed to slow down Alzheimer's by up to 61%.
Link or Reference
Publication date
27/10/18
Scientific scope
Biological
Glosari
The subject of this news did not contain a very specific vocabulary that I did not understand.
Text commentary
Alzheimer's is a very serious disease that disables people and can affect anyone, although it is true that there are factors that increase the risk of suffering it. So far all the advances that have been made have not been effective. That is why the results of this trial are very important to have slowed down this disease to 61%. This means that, in principle, this medicine can reduce the effects of the disease in more than half, which means better level and life expectancy.
For me this is simply the beginning of the cure of the disease. There is no doubt about the importance of the study, but it is clear that it is one more step. It must be taken into account that medical studies must be tested and examined until it is proven to be totally safe. There is no doubt that work should continue on these projects and continue to finance these studies that improve people's lives. Medical research, especially, is very important to improve the lives of people. In the case of Alzheimer's, I am sure that within a few years it will be possible to reduce not 61%, but 80-90% until this serious disease can be treated.